Seattle Children's Hospital, dba Seattle Children's Research Institute;Fred Hutchinson Cancer Research Center
发明人:
Michael C. Jensen,Stanley R. Riddell,Michael Hudecek
申请号：
US15817002
公开号：
US20180200298A1
申请日:
2017.11.17
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
